Onconova Therapeutics, Inc. — Q1 2020 Form 10-Q
Entity note: The supplied filing is for Onconova Therapeutics, Inc., although the request identifies Traws Pharma, Inc. The summary below reflects the filing text. Financial statements are unaudited and cover the quarter ended March 31, 2020.
Business context and reporting period
Onconova is a clinical-stage biopharmaceutical company developing oncology drug candidates. Its lead program is rigosertib, including a Phase 3 trial for higher-risk myelodysplastic syndromes (MDS). The company reported no material change in its single operating segment.
Financial results and liquidity
| Metric | Q1 2020 | Q1 2019 / prior date |
|---|---|---|
| Revenue | $52,000 | $68,000 |
| Operating expenses | $5.177 million | $7.309 million |
| Operating loss | $5.125 million | $7.241 million |
| Net loss | $5.092 million | $7.600 million |
| Net loss per share, basic and diluted | $0.03 | $1.29 |
| Net cash used in operations | $6.463 million | $6.601 million |
| Cash and cash equivalents | $31.036 million | $22.726 million at Dec. 31, 2019 |
| Working capital | $25.0 million | — |
| Total liabilities | $10.725 million | $12.100 million at Dec. 31, 2019 |
Revenue was principally SymBio license and collaboration revenue. The filing does not present a meaningful operating margin given the very small revenue base and continuing development costs. No conventional debt balance is shown; liabilities include accounts payable, accrued expenses, deferred revenue and a $176,000 warrant liability.
Financing activities provided $14.779 million, comprising approximately $9.0 million net proceeds from a January stock offering and $5.7 million from warrant exercises. Cash increased by $8.310 million during the quarter. The company had an accumulated deficit of $408.491 million.
Changes versus the prior comparable period
- Net loss narrowed by $2.508 million; operating expenses declined by $2.132 million. General and administrative costs fell 44%, primarily because Q1 2019 included workforce-reduction severance and higher stock compensation. R&D costs decreased 13%, mainly due to lower personnel and stock compensation costs.
- Revenue decreased $16,000, or 24%, due to lower clinical supply revenue from SymBio.
- Operating cash use was broadly similar year over year, down $138,000. Financing cash flow rose substantially from $33,000 to $14.779 million.
- Shares issued and outstanding increased from 111.2 million at year-end 2019 to 167.4 million at March 31, 2020, reflecting the offering and warrant exercises. Weighted-average shares were 160.3 million versus 5.9 million in Q1 2019.
Outlook, commentary and material risks
- Management expected the $31.0 million cash balance to fund operations and ongoing trials into the third quarter of 2021, while stating that substantial additional financing would be needed. The company expected continued losses and 2020 net cash expenditures comparable to 2019; it warned that failure to raise capital could force program reductions or threaten continuation of operations.
- The Phase 3 INSPIRE trial completed enrollment of 360 patients in March 2020. More than 85% of the required death events had been reported; topline survival data was anticipated in the second half of 2020 after at least 288 confirmed deaths. The company remained blinded to interim results.
- COVID-19 was affecting study timelines and created risks to enrollment, trial-site operations, manufacturing, supply chains and financing. Enrollment in an investigator-initiated lung cancer study was temporarily on hold.
- The HanX rigosertib agreement for Greater China was deemed void ab initio in January 2020 after HanX failed to meet obligations; rights reverted to Onconova. Separately, the Chinese IND for ON 123300 was approved in January. The company anticipated a U.S. IND filing in Q4 2020, subject to manufacturing data and planned work.
- Onconova was out of compliance with Nasdaq’s minimum bid-price requirement as of March 31. Nasdaq extended the compliance deadline to August 17, 2020; a proposed reverse split required stockholder approval. Delisting could impair trading liquidity and access to capital.
- The filing reports no pending material legal proceedings. Management concluded disclosure controls were effective and reported no material quarterly change in internal control over financial reporting.
Important facts for investors to verify
- Confirm the correct issuer: the filing names Onconova Therapeutics, Inc., not Traws Pharma, Inc.
- Track INSPIRE’s required death-event threshold, topline timing and full trial results; the data were not yet available in this filing.
- Assess cash runway against actual operating burn and the need, timing and terms of additional financing, including potential dilution or program cuts.
- Verify Nasdaq bid-price compliance, the status of the reverse-split proposal and any potential delisting developments.
- Monitor COVID-19 effects on trial execution, manufacturing and the projected ON 123300 U.S. IND timetable.